Adagene Announces Poster Presentation On Optimal Dose Selection For Masked Anti-CTLA-4 SAFEbody ADG126 At Upcoming Society For Immunotherapy Of Cancer 38th Annual Meeting

Author: Benzinga Newsdesk | October 12, 2023 08:06am

- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort –

SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego.

Details for the poster include:

Title: Optimal Dose Selection of ADG126 (a Masked anti-CTLA-4 SAFEbody®) with Significantly Widened Therapeutic Index compared to Ipilimumab in Combination with anti-PD-1 Antibodies Informed by QSP Modeling

• Date: Friday, November 3
• Poster Hall Hours: 9:00 a.m. – 7:00 p.m. (Reception: 5:10 p.m. – 6:40 p.m.)
• Onsite Location: Exhibit Halls A and B1 – San Diego Convention Center
  • Abstract Number: 847

Posted In: ADAG